CD99 is a therapeutic target on disease stem cells in myeloid malignancies

Autor: Ari Melnick, Ross L. Levine, Mona Khalaj, Stephen S. Chung, Montreh Tavakkoli, Martin Carroll, Wenhuo Hu, Christopher Y. Park, Virginia M. Klimek, William S. Eng, Francine E. Garrett-Bakelman
Rok vydání: 2017
Předmět:
Zdroj: Science Translational Medicine. 9
ISSN: 1946-6242
1946-6234
Popis: Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) are initiated and sustained by self-renewing malignant stem cells; thus, eradication of AML and MDS stem cells is required for cure. We identified CD99 as a cell surface protein frequently overexpressed on AML and MDS stem cells. Expression of CD99 allows for prospective separation of leukemic stem cells (LSCs) from functionally normal hematopoietic stem cells (HSCs) in AML, and high CD99 expression on AML blasts enriches for functional LSCs as demonstrated by limiting dilution xenotransplant studies. Monoclonal antibodies (mAbs) targeting CD99 induce the death of AML and MDS cells in a SRC-family kinase dependent manner in the absence of immune effector cells or complement, and administration of anti-CD99 mAbs exhibit anti-leukemic activity in AML xenografts. These data establish CD99 as a novel marker of AML and MDS stem cells, as well as a promising therapeutic target in these disorders.
Databáze: OpenAIRE